Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab + ECX in advanced gastric cancer
NCT00719550Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2009
- Primary completion
- Nov 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 2 trial of rilotumumab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by Amgen. Started Feb 2009; status: completed.
02
Drugs
rilotumumab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT00719550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719550.